Trump Signs Executive Order 14401 to Accelerate Medical Treatments for Serious Mental Illness
On April 18, 2026, President Donald J. Trump signed Executive Order 14401 at the White House, directing federal agencies to accelerate innovative research models and appropriate drug approvals for serious mental illness, with psychedelic drugs, including ibogaine compounds, named as a focus.
The order states that more than 14 million American adults have a serious mental illness and about 8 million are on prescription medication for these conditions; that suicide rates rose 37 percent from 2000 to 2018; and that more than 6,000 veterans die by suicide each year, at a rate more than twice that of non-veteran adults. It says many patients with major depressive disorder, substance use disorder, and other serious illnesses relapse or do not fully respond to standard therapies, and that the research system has yet to produce approved therapies delivering enduring improvement for the most complex patients.
On approvals, the order directs the Commissioner of Food and Drugs to provide Commissioner's National Priority Vouchers to appropriate psychedelic drugs that have received Breakthrough Therapy designation. The FDA and the Drug Enforcement Administration are to establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act, including Schedule I handling authorizations for treating physicians and researchers.
On funding and collaboration, the Secretary of Health and Human Services, through the Advanced Research Projects Agency for Health, is to allocate at least $50 million from existing funds to support state governments that have enacted or are developing psychedelic-drug programs, with technical assistance and data sharing. HHS, the FDA, and the Department of Veterans Affairs are to sign data-sharing memoranda to increase clinical trial participation and real-world evidence generation.
The order also directs the Attorney General to initiate and complete review of any Schedule I product that has successfully completed Phase 3 trials for a serious mental health disorder, so that rescheduling, if appropriate, can proceed as quickly as practicable once the product is approved.
Related: Trump Signs Executive Order 14390 to Combat Cybercrime and Fraud Targeting Americans
Source: The White House
Published by GSM · USA (original Chinese edition)
Photo: GSM 行政令统一模板（美国总统行政令）
